Trial Profile
A randomized, placebo controlled, double-blind, parallel group, international study to evaluate the safety and efficacy of rituximab (Mabthera/Rituxan) in combination with methotrexate, compared to methotrexate monotherapy, in patients with active rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methotrexate; Methotrexate; Methylprednisolone
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SERENE
- Sponsors Genentech
- 22 May 2019 This trial is Discontinued in Ireland
- 20 May 2010 Status changed from active, no longer recruiting to completed.
- 20 May 2010 Results have been reported in Annals of the Rheumatic Diseases : Published Online First 20 May 2010.